drugset / Trial / NCT06158399
AZA Combined With RCHOP in P53-mutated DLBCL.
Phase 2
Recruiting
52 enrolled
The First Affiliated Hospital of Xiamen University
Chinese Academy of Medical Sciences · collabJiangsu Provincial People's Hospital · collabShanxi Province Cancer Hospital · collabSun Yat-sen University · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
Timeline
- Start
- 2023-11-22
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Epirubicin | Small molecule | 75 mg/m2 | Intravenous |
| Background | Liposomal adriamycin | Unknown | 25 mg/m2 | Intravenous |
| Background | Liposomal adriamycin | Unknown | 30 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 100 mg | Oral |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |